<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02803502</url>
  </required_header>
  <id_info>
    <org_study_id>CHUB-PK TGT</org_study_id>
    <nct_id>NCT02803502</nct_id>
  </id_info>
  <brief_title>Does the Thrombin Generation Test Performed During the Pharmacokinetic Profile of the Substitutive Factor VIII Bring Benefits to the Personalized Treatment of Pediatric Patients and Adult Hemophilia A Patients Under Prophylaxis ?</brief_title>
  <official_title>Does the Thrombin Generation Test Performed During the Pharmacokinetic Profile of the Substitutive Factor VIII Bring Benefits to the Personalized Treatment of Pediatric Patients and Adult Hemophilia A Patients Under Prophylaxis ?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brugmann University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brugmann University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the context of hemophilia, it is well know that the level of factor VIII alone does not
      reflect the clinical phenotype of the patients in an accurate way. At equal factor VIII
      levels, certain patients will bleed more than others.

      The thrombin generation test (TGT) is a test that seems to provide a better prediction of the
      overall hemostatic status of an individual patient. In a previous study, the investigators
      have established normal reference values of the thrombin generation curve in children aged 6
      months to 16 years and adults. The goal was to evaluate the use of this test in different
      clinical contexts and in severe hemophilia patients in particular. A pilot study showed that
      the patients having a thrombin generation &lt;150 had a severe phenotype, whether those who
      received an appropriate prophylaxy had a thrombin generation superior to 150.

      Moreover, the investigators now have access to a software tool that allows them to
      individually determine the pharmacokinetic profile of the factor VIII injected to each
      patient. The factor VIII concentration is measured at injection and 30 minutes, 1 hour, 2
      hours and 24 hours afterwards. The introduction of these concentrations in the software
      allows to obtain the half-life of factor for a given patient, the maximum peak, and the
      minimum factor level (though level). The injected dosis might be sufficient (disappearance of
      substantial diminution of the bleedings) or unsufficient (persisting bleeding) for a given
      patient.

      This study aims:

        -  to measure the pharmacokinetic profile of factor VIII by two different methods, the
           time-based method and the chromogenic method

        -  to correlate the results with the TGT results obtained at the same time points and
           determine which method gives the best correlation

        -  to link the clinical symptomatology (improved symptomatology or not) with the TGT
           results

        -  to determine which minimal TGT result is linked to a minimal bleeding rate

        -  to adapt the prophylactic dosis of the patient in a personalized way.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Factor VIII blood concentration - chronometric method</measure>
    <time_frame>baseline: at factor VIII injection</time_frame>
    <description>Chronometric method of FVIII dosage on STA-R PLC automate (reactive Cephascreen STAGO, Unicalibrateur STAGO, plasma deficient Cryopep, Controls STAGO)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Factor VIII blood concentration - chronometric method</measure>
    <time_frame>30 minutes after factor VIII injection</time_frame>
    <description>Chronometric method of FVIII dosage on STA-R PLC automate (reactive Cephascreen STAGO, Unicalibrateur STAGO, plasma deficient Cryopep, Controls STAGO)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Factor VIII blood concentration - chronometric method</measure>
    <time_frame>60 minutes after factor VIII injection</time_frame>
    <description>Chronometric method of FVIII dosage on STA-R PLC automate (reactive Cephascreen STAGO, Unicalibrateur STAGO, plasma deficient Cryopep, Controls STAGO)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Factor VIII blood concentration - chronometric method</measure>
    <time_frame>120 minutes after factor VIII injection</time_frame>
    <description>Chronometric method of FVIII dosage on STA-R PLC automate (reactive Cephascreen STAGO, Unicalibrateur STAGO, plasma deficient Cryopep, Controls STAGO)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Factor VIII blood concentration - chronometric method</measure>
    <time_frame>24h after factor VIII injection</time_frame>
    <description>Chronometric method of FVIII dosage on STA-R PLC automate (reactive Cephascreen STAGO, Unicalibrateur STAGO, plasma deficient Cryopep, Controls STAGO)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Factor VIII blood concentration - Chromogenic method</measure>
    <time_frame>baseline: at factor VIII injection</time_frame>
    <description>Chromogenic FVIII assay method ( &quot;BIOPHEN FVIII: C&quot; and &quot;BIOPHEN Factor IX&quot; of the firm Hyphen BioMed)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Factor VIII blood concentration - Chromogenic method</measure>
    <time_frame>30 minutes after factor VIII injection</time_frame>
    <description>Chromogenic FVIII assay method ( &quot;BIOPHEN FVIII: C&quot; and &quot;BIOPHEN Factor IX&quot; of the firm Hyphen BioMed)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Factor VIII blood concentration - Chromogenic method</measure>
    <time_frame>60 minutes after factor VIII injection</time_frame>
    <description>Chromogenic FVIII assay method ( &quot;BIOPHEN FVIII: C&quot; and &quot;BIOPHEN Factor IX&quot; of the firm Hyphen BioMed)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Factor VIII blood concentration - Chromogenic method</measure>
    <time_frame>120 minutes after factor VIII injection</time_frame>
    <description>Chromogenic FVIII assay method ( &quot;BIOPHEN FVIII: C&quot; and &quot;BIOPHEN Factor IX&quot; of the firm Hyphen BioMed)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Factor VIII blood concentration - Chromogenic method</measure>
    <time_frame>24h after factor VIII injection</time_frame>
    <description>Chromogenic FVIII assay method ( &quot;BIOPHEN FVIII: C&quot; and &quot;BIOPHEN Factor IX&quot; of the firm Hyphen BioMed)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>total thrombin generation</measure>
    <time_frame>baseline: at factor VIII injection</time_frame>
    <description>the measurement of thrombin generation is performed by the technique of calibrated and automated Thrombinography (CAT) developed by Hemker HC. This technique allows the simultaneous analysis of multiple samples using a fluorometer (Fluoroscan Ascent, ThermoLabsystems OY, Helsinki, Finland) and a Thrombinoscope® software that converts the fluorescence intensity obtained by concentration of active thrombin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>total thrombin generation</measure>
    <time_frame>30 minutes after factor VIII injection</time_frame>
    <description>the measurement of thrombin generation is performed by the technique of calibrated and automated Thrombinography (CAT) developed by Hemker HC. This technique allows the simultaneous analysis of multiple samples using a fluorometer (Fluoroscan Ascent, ThermoLabsystems OY, Helsinki, Finland) and a Thrombinoscope® software that converts the fluorescence intensity obtained by concentration of active thrombin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>total thrombin generation</measure>
    <time_frame>60 minutes after factor VIII injection</time_frame>
    <description>the measurement of thrombin generation is performed by the technique of calibrated and automated Thrombinography (CAT) developed by Hemker HC. This technique allows the simultaneous analysis of multiple samples using a fluorometer (Fluoroscan Ascent, ThermoLabsystems OY, Helsinki, Finland) and a Thrombinoscope® software that converts the fluorescence intensity obtained by concentration of active thrombin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>total thrombin generation</measure>
    <time_frame>120 minutes after factor VIII injection</time_frame>
    <description>the measurement of thrombin generation is performed by the technique of calibrated and automated Thrombinography (CAT) developed by Hemker HC. This technique allows the simultaneous analysis of multiple samples using a fluorometer (Fluoroscan Ascent, ThermoLabsystems OY, Helsinki, Finland) and a Thrombinoscope® software that converts the fluorescence intensity obtained by concentration of active thrombin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>total thrombin generation</measure>
    <time_frame>24h after factor VIII injection</time_frame>
    <description>the measurement of thrombin generation is performed by the technique of calibrated and automated Thrombinography (CAT) developed by Hemker HC. This technique allows the simultaneous analysis of multiple samples using a fluorometer (Fluoroscan Ascent, ThermoLabsystems OY, Helsinki, Finland) and a Thrombinoscope® software that converts the fluorescence intensity obtained by concentration of active thrombin.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hemophilia</condition>
  <arm_group>
    <arm_group_label>hemophilia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with severe hemophilia (or moderate hemophilia if presence of hemorrhages) under prophylaxy and subjected to a pharmacokinetic profile of factor VIII</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Chronometric method</intervention_name>
    <description>Chronometric method of FVIII dosage on STA-R PLC automate (reactive Cephascreen STAGO, Unicalibrateur STAGO, plasma deficient Cryopep, Controls STAGO)</description>
    <arm_group_label>hemophilia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Chromogenic method</intervention_name>
    <description>Chromogenic FVIII assay method ( &quot;BIOPHEN FVIII: C&quot; and &quot;BIOPHEN Factor IX&quot; of the firm Hyphen BioMed)</description>
    <arm_group_label>hemophilia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Thrombin generation test (TGT)</intervention_name>
    <description>Briefly: the measurement of thrombin generation is performed by the technique of calibrated and automated Thrombinography (CAT) developed by Hemker HC. This technique allows the simultaneous analysis of multiple samples using a fluorometer (Fluoroscan Ascent, ThermoLabsystems OY, Helsinki, Finland) and a Thrombinoscope® software that converts the fluorescence intensity obtained by concentration of active thrombin. The reagent &quot;PPP-reagent Low&quot; respectively containing 1pm FT and 4μM phospholipid (PL) as a final concentration will be used.</description>
    <arm_group_label>hemophilia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with severe or moderate hemophilia, on prophylaxis, and suffering from
             bleedings.

        Exclusion Criteria:

          -  Patients with difficult venous access

          -  Patients who have had surgery or trauma in the month before, patients with acute
             disease (infection, inflammation)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Demulder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Brugmann</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Demulder, MD</last_name>
    <phone>024773990</phone>
    <email>Anne.DEMULDER@chu-brugmann.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Demulder, MD</last_name>
      <phone>024773990</phone>
      <email>Anne.DEMULDER@chu-brugmann.be</email>
    </contact>
    <investigator>
      <last_name>Anne Demulder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HUDERF</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Demulder, MD</last_name>
      <phone>02 477 39 90</phone>
      <email>Anne.DEMULDER@chu-brugmann.be</email>
    </contact>
    <investigator>
      <last_name>Anne Demulder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional de la Citadelle de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc Minon, MD</last_name>
      <phone>32 4 223 87 81</phone>
      <email>jean.marc.minon@chrcitadelle.be</email>
    </contact>
    <investigator>
      <last_name>Jean-Marc Minon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHC de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laure Gilis, MD</last_name>
      <phone>04.224.89.90</phone>
      <email>Laure.gilis@chc.be</email>
    </contact>
    <investigator>
      <last_name>Laure Gilis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Liège Sart Tilman</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Peters, MD</last_name>
      <phone>32 4 366.75.36</phone>
      <email>pierre.peters@chu.ulg.ac.be</email>
    </contact>
    <investigator>
      <last_name>Pierre Peters, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Hemker HC, Giesen P, AlDieri R, Regnault V, de Smed E, Wagenvoord R, Lecompte T, Béguin S. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):249-53. Review.</citation>
    <PMID>13679651</PMID>
  </reference>
  <reference>
    <citation>Filippin L, Debaugnies F, Noubouossié D, Lê PQ, Ferster A, Demulder A. [Thrombin generation test: establishment of reference values according to age and tissue factor concentration is essential before implementation into the laboratory]. Rev Med Brux. 2011 Mar-Apr;32(2):69-73. French.</citation>
    <PMID>21688590</PMID>
  </reference>
  <reference>
    <citation>van den Berg HM, De Groot PH, Fischer K. Phenotypic heterogeneity in severe hemophilia. J Thromb Haemost. 2007 Jul;5 Suppl 1:151-6.</citation>
    <PMID>17635721</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>June 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2016</study_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brugmann University Hospital</investigator_affiliation>
    <investigator_full_name>Dr Anne Demulder</investigator_full_name>
    <investigator_title>Head of clinic</investigator_title>
  </responsible_party>
  <keyword>thrombin generation test</keyword>
  <keyword>factor VIII</keyword>
  <keyword>hemophilia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

